Embla Medical hf. (OSSUY)
| Market Cap | 1.94B -3.9% |
| Revenue (ttm) | 984.45M +12.7% |
| Net Income | 93.95M +28.5% |
| EPS | 0.22 +27.2% |
| Shares Out | n/a |
| PE Ratio | 20.62 |
| Forward PE | 18.07 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 303 |
| Open | 4.150 |
| Previous Close | 4.010 |
| Day's Range | 4.150 - 4.150 |
| 52-Week Range | 3.670 - 5.610 |
| Beta | 0.46 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 21, 2026 |
About Embla Medical
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. The Bracing and Supports segment provides os... [Read more]
Financial Performance
In 2025, Embla Medical's revenue was $928.69 million, an increase of 8.63% compared to the previous year's $854.89 million. Earnings were $83.34 million, an increase of 22.05%.
Financial StatementsNews
Embla Medical Slides: Investor presentation
Embla Medical has posted slides in relation to its latest quarterly earnings report, which was published on July 21, 2026.
Embla Medical Earnings Call Transcript: Q2 2026
Q2 2026 saw 11% local currency growth, strong margins, and robust net profit, aided by a $3M U.S. tariff refund. Prosthetics & Neuro Orthotics excelled with 12% organic growth, while Patient Care faced regional challenges. Guidance narrowed to 5%-7% growth, with a 22% EBITDA margin target.
Embla Medical Quarterly report: Q2 2026
Embla Medical has published its Q2 2026 quarterly earnings report on July 21, 2026.
Embla Medical Slides: Q2 2026
Embla Medical has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 21, 2026.
Embla Medical Earnings Call Transcript: Q2 2026
Q2 2026 saw strong organic growth, higher profitability, and robust free cash flow, led by double-digit gains in Prosthetics & Neuro Orthotics and solid performance in EMEA and APAC. Patient Care lagged but showed operational progress, while guidance was narrowed to 5%-7% organic growth for the year.
Embla Medical Quarterly report: Q2 2026
Embla Medical has published its Q2 2026 quarterly earnings report on July 21, 2026.
Embla Medical Slides: Q2 2026
Embla Medical has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 21, 2026.
Embla Medical Slides: R&D presentation
Embla Medical has posted slides in relation to its latest quarterly earnings report, which was published on June 24, 2026.
Embla Medical Earnings Call Transcript: Q1 2026
Q1 2026 saw 15% revenue growth (4% organic), stable margins despite tariffs and FX, and 21% bottom-line growth. Guidance for 5%-8% organic growth and 20%-22% EBITDA margin is reiterated, with segment strength in Prosthetics and neuro-orthotics and recovery expected in Patient Care.
Embla Medical Quarterly report: Q1 2026
Embla Medical has published its Q1 2026 quarterly earnings report on April 28, 2026.
Embla Medical Slides: Q1 2026
Embla Medical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
Embla Medical Earnings Call Transcript: Q1 2026
Q1 2026 saw 15% reported sales growth and 21% net profit growth, with strong Prosthetics & Neuro Orthotics performance and margin pressure from FX and tariffs. Full-year guidance for 5%-8% organic growth and 20%-22% EBITDA margin is reiterated.
Embla Medical Quarterly report: Q1 2026
Embla Medical has published its Q1 2026 quarterly earnings report on April 28, 2026.
Embla Medical Slides: Q1 2026
Embla Medical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
Embla Medical Slides: Investor presentation
Embla Medical has posted slides in relation to its latest quarterly earnings report, which was published on April 28, 2026.
Embla Medical Transcript: Life Science-dagen 2026
A global leader in mobility solutions is driving growth through innovation, acquisitions, and expanding access to advanced prosthetics and neuro-orthotics. Key growth comes from functional trade-up, recurring sales, and new market penetration, while challenges include reimbursement, tariffs, and geopolitical risks.
Embla Medical Slides: FY 2026
Embla Medical has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 4, 2026.
Embla Medical Earnings Call Transcript: Q4 2025
Solid organic and acquisition-driven growth was achieved, with strong cash flow and resilient margins despite tariffs and FX headwinds. Guidance for 2026 anticipates 5%-8% organic growth and 20%-22% EBITDA margin, supported by efficiency gains and new product launches.
Embla Medical Annual report: Q4 2025
Embla Medical has published its Q4 2025 annual report on February 3, 2026.
Embla Medical Quarterly report: Q4 2025
Embla Medical has published its Q4 2025 quarterly earnings report on February 3, 2026.
Embla Medical Slides: Q4 2025
Embla Medical has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 3, 2026.
Embla Medical Earnings Call Transcript: Q4 2025
Solid organic sales growth of 6% for 2025 was driven by strong performance in prosthetics and neuroorthotics, with robust cash flow and a stable EBITDA margin. 2026 guidance targets 5%-8% organic growth and a 20%-22% EBITDA margin, with continued focus on patient care improvements and managing external headwinds.
Embla Medical Annual report: Q4 2025
Embla Medical has published its Q4 2025 annual report on February 3, 2026.
Embla Medical Quarterly report: Q4 2025
Embla Medical has published its Q4 2025 quarterly earnings report on February 3, 2026.
Embla Medical Slides: Q4 2025
Embla Medical has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 3, 2026.